Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (167)	8/8/2006 12:44:57 PM
From: idos	Respond to of 3027

I kind of hesitated when it went below 15 for some time and added 100 more...

To: tuck who wrote (167)	8/8/2006 2:02:16 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 3027

Just listened to the CC on replay to see if there was something there to account for the sell-off. Answer - no. :-) Unless the comments about the Sandos deal needing Scott Hart Rodino clearence surprised the market. My guess is that this is just a formality. A few points: - M356 is the descriptor being used for Copaxone, I think - Trial of the Teva/Amphistar matter will be bifurcated with a Phase I trial of the inequitable conduct charge. Inferentially this will happen this year and sooner than December. Judge Oranna Bumgarner Felter will try the case. (DC Dist Ct) - M118 had some very promising findings in a dog study - Q&A answer suggested IND to NDA at under 30 months If anyone else sees a reason for the sell-off I would like to know. :-) ij